USPTO serial 98072031
NVELOP
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- SWIFT, GILBERT M
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NVELOP?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ava R. Shelby
Ava R. Shelby WILSON SONSINI GOODRICH & ROSATI650 PAGE MILL ROADPALO ALTO, CA 94304-1050United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical preparations for gene therapy and gene editing; drug delivery agents that facilitate delivery of pharmaceuticals, namely, drug delivery agents consisting of particles in the nature of virus-like particles that facilitate delivery of a wide range of pharmaceuticals; drug carriers for medical use, namely, drug delivery agents in the form of engineered particles in the nature of virus-like particles that facilitate the delivery of pharmaceutical preparations for delivering drugs to human organs; cell and gene therapy products for increasing protein expression in cells, namely, engineered virus-like particles; pharmaceutical and biological preparations for delivering proteins into cells for the prevention, diagnosis and treatment of genetic diseases, namely, cancer, including hematological and solid tumors, autoimmune diseases, cardiovascular disease, respiratory disease, pulmonary disease, central nervous system diseases and disorders, mitochondrial diseases and disorders, endocrine disorders, gastrointestinal diseases, auditory processing disorders (APD) and hearing loss disorders, inflammatory diseases, acquired and innate immunodeficiencies, kidney disease, liver disease, metabolic diseases and disorders, musculoskeletal disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, brain disorders and diseases, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes; pharmaceutical and biological preparations for delivering therapeutic proteins for treatment of cancer, including hematological and solid tumors, autoimmune diseases, cardiovascular disease, respiratory disease, pulmonary disease, central nervous system diseases and disorders, mitochondrial diseases and disorders, endocrine disorders, gastrointestinal diseases, genetic diseases and disorders, auditory processing disorders (APD) and hearing loss disorders, inflammatory diseases, acquired and innate immunodeficiencies, kidney disease, liver disease, metabolic diseases and disorders, musculoskeletal disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, brain disorders and diseases, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes | ACTIVE | — |
| 042 | medical and scientific research in the fields of gene therapy, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, cell therapy, therapeutic proteins, protein expression, protein delivery and drug delivery; services in the field of production of cell therapies namely, scientific research and medical research in the field of gene editing technology featuring gene-editing and protein delivery; pharmaceutical research services; pharmaceutical drug development services; medical and scientific research for the treatment of genetic diseases and disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Nvelop Therapeutics, Inc.
- Other trademarks owned by Nvelop Therapeutics, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named NVELOP
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 29, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 29, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 25, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 31, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 31, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 25, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 6, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 26, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 25, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 25, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 1, 2024 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Nov 1, 2024 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Nov 1, 2024 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 7, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Oct 7, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jul 13, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 13, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 13, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 20, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 20, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 20, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 10, 2024 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jun 10, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 10, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 10, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 21, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 21, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 21, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 16, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 5, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 8, 2023 | NWAP | NEW APPLICATION ENTERED | — |